Aperion Biologics

About:

Aperion Biologics is a clinical-stage medical device company developing a technique to make animal-tissues usable for human applications.

Website: http://aperionbiologics.com

Twitter/X: AperionBio

Top Investors: Deutsche Bank, Hasso Plattner Ventures, Lurie Investment Fund

Description:

Aperion Biologics is a clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology. It develops a technique to make animal-tissues usable for human applications without causing rejection. The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both “humanizes” and sterilizes the tissues without affecting their biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled. Aperion’s Z-Process of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to valves and vessels to soft tissue grafts for augmentation and repair. Aperion Biologics was founded in 2008 and is headquartered in San Antonio, Texas.